%0 Journal Article
%T [Consideration on the Research and Development of Anti-tumor Bispecific Antibody Drugs].
%A Song Y
%A Tang L
%A Xia L
%A Tong X
%A Yang Z
%A Song Y
%A Tang L
%A Xia L
%A Tong X
%A Yang Z
%J Zhongguo Fei Ai Za Zhi
%V 25
%N 9
%D Sep 2022 20
%M 36172734
暂无%R 10.3779/j.issn.1009-3419.2022.101.43
%X The drugs of programmed cell death 1 and its ligand 1 immune checkpoint inhibitors have ushered in a new era of anti-tumor immunotherapy, which has shown outstanding efficacy in some tumors, such as Hodgkin lymphoma, but there is still low response rate in some kinds of tumors. In recent years, bispecific antibodies prepared by cell fusion, recombinant DNA, protein engineering and other technologies can specifically bind two antigens or epitopes at the same time or successively, play a synergistic role in tumor treatment, can effectively inhibit tumor immune escape, and improve the effect of anti-tumor treatment has become a hot spot in tumor research. This paper will summarize the clinical research and development of bispecific antibodies, to provide reference for the industry.
.<BR>【中文题目：抗肿瘤双特异性抗体研究进展与临床研发
关注要点】 【中文摘要：以程序性死亡受体1及其配体1免疫检查点抑制剂为代表的药物上市，开启了抗肿瘤免疫治疗的新时代，该类药物在某些肿瘤中表现出较为突出的持续应答，如霍奇金淋巴瘤，但仍在部分肿瘤中应答率低。近年来，双特异性抗体是通过细胞融合、重组DNA、蛋白质工程等技术制备的人工抗体，可同时或先后特异性结合两个抗原或抗原表位，在肿瘤治疗中发挥协同作用，能够有效抑制肿瘤免疫逃逸，提高抗肿瘤治疗效果，成为肿瘤研发热点。本文就双特异抗体研究进展和临床研发关注要点进行综述，以期为药物研发的相关人员提供参考。
】 【中文关键词：双特异性抗体；研究进展；临床研发】.